158 related articles for article (PubMed ID: 10739683)
21. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of p53 overexpression in endometrial cancer.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Cancer Res; 1994 Sep; 54(17):4667-70. PubMed ID: 8062261
[TBL] [Abstract][Full Text] [Related]
23. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
24. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators.
Lim P; Aquino-Parsons CF; Wong F; Dupuis B; Phillips D; Zhou C; Gilks CB
Gynecol Oncol; 1999 May; 73(2):191-5. PubMed ID: 10329033
[TBL] [Abstract][Full Text] [Related]
25. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
26. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
Shvarts O; Seligson D; Lam J; Shi T; Horvath S; Figlin R; Belldegrun A; Pantuck AJ
J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252
[TBL] [Abstract][Full Text] [Related]
27. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction.
Nordström B; Strang P; Bergström R; Nilsson S; Tribukait B
Cancer; 1996 Nov; 78(9):1942-51. PubMed ID: 8909315
[TBL] [Abstract][Full Text] [Related]
28. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
29. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
30. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
31. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
Engelsen IB; Stefansson I; Akslen LA; Salvesen HB
Am J Obstet Gynecol; 2006 Oct; 195(4):979-86. PubMed ID: 16677592
[TBL] [Abstract][Full Text] [Related]
32. Lower uterine segment involvement is associated with adverse outcome in patients with stage I endometroid endometrial cancer: results of a multicenter study.
Gemer O; Gdalevich M; Voldarsky M; Barak F; Ben Arie A; Schneider D; Levy T; Anteby EY; Lavie O
Eur J Surg Oncol; 2009 Aug; 35(8):865-9. PubMed ID: 19013746
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
Mell LK; Meyer JJ; Tretiakova M; Khramtsov A; Gong C; Yamada SD; Montag AG; Mundt AJ
Clin Cancer Res; 2004 Aug; 10(16):5546-53. PubMed ID: 15328195
[TBL] [Abstract][Full Text] [Related]
34. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
35. Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma.
Schwab KV; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE
Gynecol Oncol; 2009 Jan; 112(1):146-9. PubMed ID: 18937970
[TBL] [Abstract][Full Text] [Related]
36. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.
Lee EJ; Kim TJ; Kim DS; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
Gynecol Oncol; 2010 Mar; 116(3):533-8. PubMed ID: 20006376
[TBL] [Abstract][Full Text] [Related]
37. Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater.
Ajiki T; Kamigaki T; Hasegawa Y; Fujino Y; Suzuki Y; Takeyama Y; Ku Y; Kuroda Y
Hepatogastroenterology; 2001; 48(41):1266-70. PubMed ID: 11677943
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Jeon YT; Kang S; Kang DH; Yoo KY; Park IA; Bang YJ; Kim JW; Park NH; Kang SB; Lee HP; Song YS
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1538-42. PubMed ID: 15342458
[TBL] [Abstract][Full Text] [Related]
39. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
[TBL] [Abstract][Full Text] [Related]
40. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]